Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208037 | 0.90 | ELANE (0.86) | ELANECYP3A4CYP2C9 | |
| SCHEMBL5203100 | 0.89 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL5205082 | 0.88 | ELANE (0.82) | ELANECYP3A4CYP2C9 | |
| SCHEMBL8346047 | 0.87 | ELANE (0.81) | ELANECYP3A4CYP2C9 | |
| SCHEMBL8346479 | 0.87 | ELANE (0.73) | ELANECYP3A4CYP2C9 | |
| SCHEMBL5204919 | 0.86 | ELANE (0.79) | ELANECYP3A4CYP2C9 | |
| SCHEMBL5205546 | 0.85 | ELANE (0.83) | ELANECYP3A4CYP2C9 | |
| SCHEMBL8347811 | 0.85 | ELANE (0.66) | ELANECYP3A4CYP2C9 | |
| SCHEMBL5243071 | 0.84 | ELANE (1.00) | ELANECYP3A4CYP2C9 | |
| SCHEMBL8346762 | 0.83 | ELANE (0.77) | ELANECYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554246-B1 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2007-08-22 | — | — | EP | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| WO-2004020410-A2 | DIHYDROPYRIDINONE DERIVATIVES AS HNE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | ELANE 260/4885CYP3A4 3343/4885CYP2C9 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.